Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial

被引：0
|
作者：
Peter Schmid
J. Krocker
R. Kreienberg
P. Klare
K. Kittel
H. Sommer
G. Heinrich
T. Steck
W. Lichtenegger
D. Elling
S. Kümmel
机构：
[1] Imperial College London,Department of Medical Oncology, Charing Cross Hospital
[2] Sana Hospital Lichtenberg,Department of Obstetrics and Gynecology
[3] University of Ulm,Department of Obstetrics and Gynecology
[4] Clinic for Gynaecological Oncology,Department of Obstetrics and Gynecology
[5] Ludwig Maximilians University Munich,Department of Obstetrics and Gynecology
[6] Clinic for Gynaecological Oncology,Department of Obstetrics and Gynecology
[7] Hospital Chemnitz,Department of Obstetrics and Gynecology
[8] Charité University Medical Center,undefined
[9] University Hospital Essen,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2009年 / 64卷
关键词：
Docetaxel; Non-pegylated liposomal doxorubicin; Cardiotoxicity; Metastatic breast cancer; Chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：401 / 406
页数：5
相关论文
共 50 条
  • [1] Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial
    Schmid, Peter
    Krocker, J.
    Kreienberg, R.
    Klare, P.
    Kittel, K.
    Sommer, H.
    Heinrich, G.
    Steck, T.
    Lichtenegger, W.
    Elling, D.
    Kuemmel, S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (02) : 401 - 406
  • [2] Phase II trial of non-pegylated liposomal doxorubicin (Myocet®) associated with weekly docetaxel in metastatic breast cancer
    Safina, V.
    Giuntini, N.
    Coltelli, L.
    Martella, F.
    Di Marsico, R.
    Bejtja, E.
    Giannessi, P. G.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 46 - 46
  • [3] Pegylated liposomal doxorubicin and vinorelbine in metastatic breast cancer: Final results of a phase II trial
    Elsaid, A. A.
    Awad, N. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer:: final results of a phase II trial
    Schmid, P
    Krocker, J
    Jehn, C
    Michniewicz, K
    Lehenbauer-Dehm, S
    Eggemann, H
    Heilmann, V
    Kümmel, S
    Schulz, CO
    Dieing, A
    Wischnewsky, MB
    Hauptmann, S
    Elling, D
    Possinger, K
    Flath, B
    ANNALS OF ONCOLOGY, 2005, 16 (10) : 1624 - 1631
  • [5] Non-pegylated liposomal doxorubicin and docetaxel as first-line treatment in metastatic breast cancer.
    Heilmann, V
    Eggemann, H
    Sommer, H
    Heinrich, G
    Blohmer, JU
    Mallmann, PK
    Krabisch, P
    Klare, P
    Schilling, J
    Kittel, K
    Elling, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 66S - 66S
  • [6] Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial
    S. Del Barco
    R. Colomer
    L. Calvo
    I. Tusquets
    E. Adrover
    P. Sánchez
    J. Rifà
    J. De la Haba
    J. A. Virizuela
    Breast Cancer Research and Treatment, 2009, 116 : 351 - 358
  • [7] Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial
    Del Barco, S.
    Colomer, R.
    Calvo, L.
    Tusquets, I.
    Adrover, E.
    Sanchez, P.
    Rifa, J.
    De la Haba, J.
    Virizuela, J. A.
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 116 (02) : 351 - 358
  • [8] A multicenter phase II study of non-pegylated liposomal doxorubicin (MYOCET®) in combination with trastuzumab and docetaxel as first line therapy in metastatic breast cancer
    Vanturini, M.
    Bighin, C.
    Puglisi, F.
    Contu, A.
    Aitini, E.
    Colucci, G.
    Merlano, M. C.
    Paccagnella, A.
    Marini, G.
    Crino, L.
    Djazouli, K.
    Barbato, A.
    CANCER RESEARCH, 2009, 69 (02) : 249S - 249S
  • [9] A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer
    Venturini, M.
    Bighin, C.
    Puglisi, F.
    Olmeo, N.
    Aitini, E.
    Colucci, G.
    Garrone, O.
    Paccagnella, A.
    Marini, G.
    Crino, L.
    Mansutti, M.
    Baconnet, B.
    Barbato, A.
    Del Mastro, L.
    BREAST, 2010, 19 (05): : 333 - 338
  • [10] Myotax: A phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines
    Curtit, E.
    Nouyrigat, P.
    Dohollou, N.
    Levy, E.
    Lortholary, A.
    Gligorov, J.
    Facchini, T.
    Jaubert, D.
    Maille, N.
    Pivot, X.
    Grange, V.
    Cals, L.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (16) : 2396 - 2402
12345